80 results about "Arthritis" patented technology

The present invention relates to a composition for injection into the joint cavity of dogs or cats, which is used to treat or ameliorate arthritis by injection into the joint cavity of dogs or cats, or to reduce mechanical friction in the joint region through physical restoration. The present invention also relates to a method for administering a composition for injection into the joint cavity of dogs or cats, the composition being used to treat or ameliorate arthritis by injection into the joint cavity of dogs or cats, or to reduce mechanical friction in the joint region through physical restoration. When the composition of the present invention is administered, the dose of sodium polynucleotide is 2-3 mg, preferably 2.5-3 mg, per body weight (kg) of a dog or a cat.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The disclosure describes compounds, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-CCP (anti-cyclic citrullinated peptide binding moiety). The compounds are useful in preventing, treating, and / or ameliorating various types of arthritis, including rheumatoid arthritis (RA), in a subject when administered in therapeutically effective amounts.

This invention provides a LYTACA polypeptide complex (sRD-Lytaca) targeting the degradation of soluble IL-17RD (sIL-17RD), its preparation method, and its applications. This polypeptide complex is formed by the self-assembly of the sIL-17RD-binding peptide sRDL and the scavenger receptor-binding peptide SRAL after Nap-FF modification and mixing. sRDL can be conjugated with fluorescently labeled molecules to prepare detection reagents for the detection of sIL-17RD. This invention also provides a variant with at least 80% sequence identity with sRDL and retaining binding ability, and pharmaceutical compositions containing sRDL and / or sRD-Lytaca. This invention provides a new technical means for the prevention and treatment of osteoarthritis and diseases related to sIL-17RD protein (such as rheumatoid arthritis).

The invention provides a bispecific antibody and application thereof. The bispecific antibody comprises a first structural domain and a second structural domain, wherein the first structural domain is specifically combined with an interleukin-6 receptor IL-6R, and the second structural domain is specifically combined with interleukin-23. The bispecific antibody can target IL-6R and IL-23p19 at the same time, the specificity is higher, tumor cells can be targeted more accurately, adverse reactions caused by off-target toxicity are reduced, the special function is exerted, the biological function which is difficult to achieve by monoclonal antibody drugs is achieved, compared with a combination therapy of monoclonal antibodies, the treatment cost can be effectively reduced, and the treatment effect is better. The upper limit of the curative effect on autoimmune diseases such as rheumatoid arthritis and IBD at present is broken through.

This invention discloses an arginine-glycine-aspartic acid (RGD) peptide-modified chiral atomically precise metal nanoclusters, their preparation, and applications. The RGD peptide-modified chiral atomically precise metal nanoclusters consist of an atomically precise metal core, a chiral RGD peptide ligand layer, and linking molecules connecting the metal core and ligand layer. The chiral regulation and targeting functions of the RGD peptide-modified chiral atomically precise metal nanoclusters synergistically enhance their targeting and penetration at the tissue and cellular levels, thereby improving their uptake efficiency. After optimization with α... v The binding constant of β3 integrin is 1.4 × 10⁻⁶. ‑6 M ‑1 RGD peptides modify the ultrasmall metal cores of chiral atomically precise metal nanoclusters, endowing them with highly efficient and rapid renal clearance properties. This invention provides a solution suitable for various α-cell tumors, arthritis, liver fibrosis, and other conditions. v RGD peptides modified with chiral atomic precision metal nanoclusters, used to treat diseases with high expression of β3 integrin, can achieve efficient enrichment at target sites for imaging.

The invention belongs to the technical field of biological medicine, and particularly relates to a clostridium baumannii preparation and application thereof in pet disease treatment. The clostridium baumannii is prepared into a freeze-dried microbial inoculum, the freeze-dried microbial inoculum is matched with prebiotics, and the prebiotics can provide nutritional support and enhance the biological activity of the clostridium baumannii; meanwhile, the in-vivo microecological balance can be adjusted, in addition, the protein protective agent, the saccharide protective agent and other components added into the freeze-dried microbial agent can effectively maintain the activity of the clostridium baumannii, the shelf life of the preparation is prolonged, and the stability and reliability of the clinical application effect are guaranteed. According to the invention, a dosage form with an excellent effect is obtained by screening the components with different proportions, and the dosage form shows a more excellent effect in the aspect of treating the dog and cat osteoarthritis. The clostridium baumannii preparation can effectively inhibit inflammatory response caused by arthritis and relieve inflammatory injury, and the raw materials adopted by the clostridium baumannii preparation are natural, high in safety, free of obvious toxic and side effects and suitable for different individual pets.

The present invention relates to the field of cell therapy. Disclosed are a fibroblast activation protein-targeting CAR T-cell, a preparation method therefor, and an application thereof. A CAR T-cell can be prepared by introducing an FAP-targeting chimeric antigen receptor (CAR) into a T lymphocyte, wherein the CAR in the CAR T-cell comprises a signal peptide, an antigen-binding domain, a hinge region, a transmembrane domain, a co-stimulatory signaling region, and a CD3 signaling domain. The CAR T-cell specifically recognizes the FAP by means of a single-chain variable fragment (scFv), which activates an intracellular signaling pathway, releasing cytokine IFN-γ, and exhibiting a cytotoxic effect on FAP+ cells, thereby achieving specific depletion of FAP+ cells at a lesion site. The CAR-T cell can be used for treating diseases characterized by upregulated FAP expression, such as fibrosis (pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, renal fibrosis, etc.), arthritis, autoimmune disorders (Crohn's disease, rheumatoid arthritis, etc.), and cardiovascular diseases, and demonstrates tremendous application potential and commercial value.

The present application belongs to the field of biopharmaceuticals. Disclosed is the use of a stem cell extract in the preparation of a drug for treating or preventing arthritis by regulating lysosomal and / or mitochondrial functions, wherein a method for preparing the stem cell extract comprises: S1) culturing mesenchymal stem cells and creating stress conditions to stimulate the mesenchymal stem cells; and S2) isolating and purifying a culture supernatant of the mesenchymal stem cells cultured in S1) to obtain a stem cell extract, wherein S2) comprises: S21) filtering the culture supernatant to obtain a filtrate; S22) concentrating the filtrate by means of 3KD ultrafiltration to obtain a crude sample; S23) purifying the crude sample by means of size-exclusion chromatography or reversed-phase chromatography to prepare a purified sample; and S24) preparing the purified sample into a preparation. In the present application, the culture supernatant containing secretions of the stressed stem cells is obtained by means of stress culturing of the stem cells, and in combination with a purification method, the supernatant is prepared into a preparation which can be used for treating arthritis.

The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.

The application belongs to the technical field of biotechnology, and particularly relates to an anti-TL1A nanobody and application thereof. The amino acid sequences of the complementarity determining regions CDR1, CDR2 and CDR3 of the nanobody are respectively shown as SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO:1. The application uses a llama natural nanobody library and combines phage display technology to successfully screen a high-affinity nanobody targeting TL1A. The antibody can specifically recognize human TL1A protein and a TL1A overexpression cell line, and has high affinity, high specificity and good physicochemical stability. Based on the characteristic of targeting TL1A, the nanobody has important application value in the precise diagnosis and targeted treatment of TL1A high-expression related diseases such as inflammatory bowel disease, rheumatoid arthritis, asthma and fibrosis, and is particularly suitable for developing a high-sensitivity in-vitro diagnostic kit and a novel biological therapeutic drug.

Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral calcinosis. Also disclosed are agonists of GLP-1R, GCGR, and / or GIPR, and methods of treating various therapeutic indications by administering an effective amount of an agonist of GLP-1R, GCGR, and / or GIPR.

This invention relates to the technical field of nanomedicine synthesis and discloses a method for synthesizing nanomedicines for the treatment of rheumatoid arthritis, comprising the following steps: S10: obtaining or preparing high-purity, small-particle-size CaO2 nanoparticles; S20: encapsulating the CaO2 nanoparticles in a ZIF67 system to obtain CaO2@ZIF67; S30: dissolving methotrexate in methanol to obtain an MTX additive solution; dissolving CaO2@ZIF67 in methanol, then adding the MTX additive solution dropwise, and stirring thoroughly; finally, purifying, washing, and drying the obtained product to obtain CaO2@MTX@ZIF67. Targeting the two main pathological features of rheumatoid arthritis, namely inflammation and hypoxic microenvironment, this invention uses ZIF67-loaded calcium peroxide combined with methotrexate to treat the inflammatory sites of rheumatoid arthritis. The constructed product can inhibit the expression of tumor necrosis factor-α / interleukin-6, overcome the hypoxic nature of rheumatoid arthritis, and achieve the technical characteristics of alleviating inflammatory symptoms and altering disease progression, low cost, few side effects, and long-term treatment.

The present application relates to the technical field of traditional Chinese medicine composition, and discloses a traditional Chinese medicine composition for relieving rheumatoid arthritis and a preparation method thereof, which comprises Qingfengteng, Huangqi, Chuanshanyang, propolis, turmeric, Fuling, soybean isoflavone peptide, chitosan, Gancao, Chufu, Guizhi and Dangui, and the preparation method comprises raw material pretreatment, extraction, active ingredient mixing and preparation forming. The traditional Chinese medicine composition prepared by the present application has a maximum inhibition rate of 88.6% and 86.4% on TNF-alpha and IL-6, a bioavailability of 87.5%, and can improve immune function and quickly relieve joint swelling and pain. Moreover, the preparation process of the composition is stable and suitable for industrial production, and the composition has significant clinical application value in the treatment of rheumatoid arthritis.

This invention belongs to the field of biopharmaceuticals, specifically relating to an endoplasmic reticulum-targeting antioxidant nanozyme, its preparation method, and its applications. The novel antioxidant nanozyme (Arg-Mnzyme) provided by this invention can effectively inhibit NOX1 expression, eliminate the accumulation of reactive oxygen species, and inhibit NOX1 activation and oxidative stress after temporomandibular joint arthritis-related pain, thus alleviating pain hypersensitivity. Compared to natural enzymes, nanozymes have stronger modifiability; this invention will construct an endoplasmic reticulum-precise antioxidant nanozyme to achieve precise regulation of oxidative stress.

The present invention relates to compositions and methods utilizing anti-TNF antibodies, e.g., the anti-TNF antibody golimumab having a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO:36 and a light chain (LC) comprising an amino acid sequence of SEQ ID NO:37, for use in the treatment of juvenile idiopathic arthritis (JIA), and in particular for polyarticular juvenile idiopathic arthritis (pJIA).

Disclosed are peptide-fatty acid conjugates, pharmaceutical compositions containing them, and methods of their medical use in the treatment of, e.g., a disease or condition associated with the PTHR1 signaling overactivity (e.g., hypercalcemia, hypophosphatemia, hyperparathyroidism, or Jansen's metaphyseal chondrodysplasia) or deficiency (e.g., hypoparathyroidism, hyperphosphatemia, osteoporosis, fracture repair, osteomalacia, arthritis, thrombocytopenia, or chronic kidney disease).

This invention belongs to the field of biomedical technology, specifically relating to an ointment and its application. The toad oil used in this invention differs significantly in composition from toad venom, and its ointment is effective for various acute and chronic pain conditions. Animal experiments have confirmed that the toad oil ointment significantly reduces the frequency and delays the onset of acetic acid-induced writhing responses, demonstrating a clear analgesic effect. Clinical studies have shown that this ointment is rapidly effective and has a definite therapeutic effect on acute gout attacks, postherpetic neuralgia, and arthritis-related pain and swelling. The formulation effectively improves drug retention and user comfort, and no skin irritation has been observed. This development achieves comprehensive utilization of toad resources, providing an example for the sustainable development of traditional Chinese medicine and the efficient utilization of biological resources.

The application discloses an oral polypeptide preparation for preventing and treating rheumatoid arthritis. The application provides an oral polypeptide preparation for treating or preventing rheumatoid arthritis, and an active ingredient of the oral polypeptide preparation is a polypeptide shown in SEQ ID No. 1, and the polypeptide shown in SEQ ID No. 1 is loaded in dextran particles to form the oral polypeptide preparation. The oral polypeptide preparation can effectively inhibit secretion of inflammatory cytokines in a local rheumatoid arthritis, and delay or prevent disease progression. The oral polypeptide preparation has important application prospects in treating rheumatoid arthritis.

1. Name of the product in this design: Handheld Ultrasonic Therapy Device. 2. Purpose of this design: To relieve pain and inflammation caused by soft tissue injuries such as muscles, tendons, and ligaments, and to assist in the treatment of joint conditions such as arthritis to reduce stiffness and pain. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

This invention proposes a method for constructing an animal model for the prevention of temporomandibular joint osteoarthritis (TMJ) by knocking out the FAM20C gene, belonging to the field of pharmaceutical technology. It solves the problem of providing effective treatment and prevention methods for TTMJ osteoarthritis. It includes the application of the FAM20C gene in the preparation of drugs for the prevention or treatment of TTMJ osteoarthritis. It is mainly used for the prevention or treatment of TTMJ osteoarthritis.

A chitosan thermosensitive glue composition for treating osteoarthritis and a preparation method thereof. The composition comprises 0.5-5% chitosan thermosensitive glue and 10 6 -10 7 / mL stem cells. After mixing mesenchymal stem cells with chitosan thermosensitive glue, the mixture is injected into the joint cavity, which can not only play the effect of chitosan gel in lubricating the joint, but also inhibit inflammatory factors secreted by mesenchymal stem cells, and at the same time, mesenchymal stem cells can promote the regeneration of chondrocytes, effectively treating osteoarthritis.

The application discloses a hot compress magnetotherapy glove with drug penetration assistance, and belongs to the technical field of arthritis treatment gloves.The hot compress magnetotherapy glove comprises a main body, a hot compress magnetotherapy mechanism is arranged in the main body, the hot compress magnetotherapy mechanism comprises a bracelet controller, one end of the bracelet controller is connected with a peristaltic pump through a wire, one side of the peristaltic pump is connected with a medicine bag through a catheter, both sides of the peristaltic pump are connected with medicine guide tubes, the medicine guide tubes are attached to the inner wall of a glove cavity, and one end of the glove cavity is connected with a finger cavity.The hot compress magnetotherapy glove generates ultrasonic waves of a specific frequency through a regulated micro ultrasonic transducer; the mechanical effect of the ultrasonic waves makes the cell gap of the cutin layer of the skin larger, the thermal effect promotes blood circulation of the skin, the cavitation effect forms micro cavities on the surface of the skin, and the three auxiliary combinations of the neodymium-iron-boron permanent magnet and the heating layer enhance the drug permeability, so that the drug molecules diffuse and absorb to the joint tissue, and the use of the patient is facilitated.

This application provides a method for preventing or treating periarthritis of a prosthesis (PJI), or a method for alleviating PJI-related symptoms. The method comprises administering a therapeutic agent into the joint of a patient in need, the therapeutic agent comprising a compound represented by formula (I) and / or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, metabolite, or deuterated thereof. TIFF2026520113000009.tif77170

This invention discloses a method for predicting the efficacy of rheumatoid arthritis treatment based on multimodal feature fusion, relating to the fields of artificial intelligence and medical information processing. This method, targeting rheumatoid arthritis patients, integrates ultrasound images, radiomics features, and clinical characteristics to predict the efficacy response of traditional slow-acting antirheumatic drugs (csDMARDs). Specifically, it includes: standardizing and enhancing ultrasound images; extracting image depth features using a pre-trained ResNet convolutional neural network as the backbone model; extracting and standardizing radiomics and clinical features, and fusing them with image depth features through a Cross-Attention mechanism; optimizing feature distribution using supervised contrastive learning (SupConLoss) to improve model discriminative ability; and finally outputting the treatment response category through a fully connected layer. This invention establishes a high-performance predictive model with promising clinical applications by integrating ultrasound images, radiomics, and clinical data.

This invention relates to a compound gel for treating joint inflammation based on a modified ancient Chinese medicine formula, belonging to the fields of pharmaceutical preparations and traditional Chinese medicine. The compound gel consists of active ingredient extracts, a poloxamer thermosensitive gel matrix, a penetration enhancer, a humectant, and deionized water. The active ingredient extracts are obtained from *Terminalia chebula*, *Amla emblica*, lavender, wild watermelon, *Artemisia annua*, and chamomile through ultrasonic-microwave coupling extraction. Using ultrasonic-microwave coupling extraction combined with a low-temperature drying process, small-molecule active ingredients are obtained. A body temperature-responsive gel is constructed based on poloxamer 407 / 188, achieving in-situ phase transition on the skin surface and stable sustained release over 6-8 hours, significantly improving transdermal absorption. The gel is combined with an integrated medication container and biomimetic protective gear to form a synergistic drug delivery system, achieving closed-loop controlled release, leak-proof design, and motion adaptation. This gel is non-irritating and non-allergenic, suitable for topical treatment of osteoarthritis, rheumatoid arthritis, and soft tissue injuries caused by cold and dampness in high-altitude regions.

FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to neurology, traumatology, and orthopedics. It can be used in the treatment of pain syndrome in patients with osteoarthritis of large joints. The method involves conducting 5-10 xenon therapy procedures using the Carboxica device. The drug is injected subcutaneously, para-articularly around the joint at a distance of 2-3 cm from each other, with an interval of 48 hours. The xenon dosage per procedure is 5 ml / kg of the patient's weight.EFFECT: method is available, increases the effectiveness of treating pain syndrome in patients, and has a long-term analgesic effect.1 cl, 3 tbl, 3 ex

The application discloses application of a substance with increased OSKM content or activity in preventing joint cartilage aging and treating osteoarthritis diseases. The OSKM of the application is obtained by connecting Oct4, Sox2, Klf4 and C-Myc. The experiment of the application proves that the OSKM or the substance with increased OSKM content or activity has a definite effect in preventing joint cartilage aging and treating osteoarthritis diseases, the application provides a new strategy for developing gene therapy for preventing joint cartilage aging and treating osteoarthritis diseases, and expands the selectable range of clinical gene therapy and drug therapy.